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ABSTRACT
Objective: This pilot study examined the effects of atomoxetine on attention-deficit/hyperac-
tivity disorder (ADHD) symptoms and autistic features in children with pervasive develop-
mental disorders (PDD).
Method: Twelve children (aged 6–14 years) with PDD accompanied by ADHD symptoms
entered a 10-week open-label study with atomoxetine (1.19 ± 0.41 mg/kg/day). Response was
assessed by using parent and clinician rating scales with change in the ADHD-Rating Scale
(ADHDRS) as primary outcome measure.
Results: Atomoxetine reduced ADHD-symptoms as measured by the ADHDRS (44% de-
crease vs. baseline, p < 0.003), the Conners’ Parent Rating Scale—R:S (CPRS-R) (25% in the
subscale “Cognitive Problems,” p < 0.028; 32% in “Hyperactivity,” p < 0.030; and 23% in
“ADHD index,” p < 0.023). We found a reduction of 21% (p = 0.071) for changes in the sub-
scale “Hyperactivity” of the Aberrant Behavior Checklist (ABC). No change was found in any
of the other ABC subscales, nor in the subscale “Oppositional” of the CPRS-R. Five patients
(42%) discontinued because of side effects. Gastrointestinal symptoms, irritability, sleep
problems, and fatigue were the most frequent side effects.
Conclusions: These preliminary findings indicate that atomoxetine may be a promising
new agent in the treatment of ADHD symptoms in children with PDD. However, children
with PDD may have a higher vulnerability for some of the known side-effects of atomoxe-
tine.
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INTRODUCTION
CHILDREN WITH PERVASIVE DEVELOPMENTAL DISOR-DERS (PDD’s) are characterized by marked
impairments in social interaction and commu-
nication, and often show restricted repetitive
and stereotyped patterns of behavior (Volkmar
et al. 2004). A wide range of pharmacological
interventions are used to ameliorate some of the
core and secondary features, amongst which
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inattention and overactivity are the most fre-
quently targeted symptoms (Buitelaar and
Willemsen-Swinkels 2000; Aman 2004). It is
estimated that up to 20% of children with
autistic disorder are prescribed stimulant
medication to treat such behavior (Aman et
al. 1995). However, these children appear to
be particularly susceptible to some of the well-
known side effects of these agents. For
example, earlier studies found that methyl-
phenidate could worsen social withdrawal,
dullness, stereotypies, and tics, and increase
aggression and agitation when used in hyper-
active children with autistic disorder (Aman
1996; Handen et al. 2000). In a recent double-
blind, controlled dosage study of immediate-
release methylphenidate in 66 children with
pervasive developmental disorders and
hyperactivity/impulsivity, about half of the
participants responded to at least one of the
doses. Effect sizes, however, were modest and
almost 10% of the children discontinued treat-
ment due to adverse events (RUPP 2005).
These side effects significantly limit the feasi-
bility of psychostimulants in children with
PDD.
Also, while the classical antipsychotics such
as haloperidol (Anderson et al. 1989) and the
now frequently used atypical antipsychotic
agent risperidone have been shown to reduce
overactivity (RUPP 2002; Troost et al. 2005),
they do not appear to bring about improve-
ments in distractibility, inattention, or learn-
ing, as well expose children to risks for
long-term unwanted effects, including weight
gain and neurological side effects.
In the treatment of ADHD, several other
nonstimulant medications have been used, in-
cluding desipramine, bupropion, clonidine,
guanfacine, and fenfluramine (Biederman and
Spencer 2000; Scahill et al. 2001; Spencer et al.
2002). Experience with these nonstimulant
medications in autistic and developmentally
disabled populations is limited (Biederman et
al. 1989; Jaselskis et al. 1992; Aman et al. 1993;
Conners et al. 1996; Posey et al. 2004). Al-
though some supportive evidence exists for its
use in the treatment of attention-deficit/hy-
peractivity disorder (ADHD) in general, over-
all, a meager database, safety concerns, or both
limit their use.
A promising new group of medications for
the treatment of ADHD symptoms are the nor-
adrenergic reuptake inhibitors. There is a theo-
retical basis for a noradrenergic influence on
attention and executive functions (Pliszka et
al. 1996), and compounds influencing nor-
adrenergic pathways are known to be effective
in the treatment of ADHD (Biederman and
Spencer 1999; Prince et al. 2000). One of the
more recent examples of this group is atomox-
etine, a potent inhibitor of the presynaptic nor-
epinephrine transporter. Atomoxetine has
been shown to be superior to placebo in treat-
ing ADHD symptoms and is in general well
tolerated in pediatric and adult studies
(Spencer et al. 1998; Michelson et al. 2001;
Buitelaar et al. 2004; Michelson et al. 2004). In
one study where atomoxetine was compared
to methylphenidate, the response rate did not
differ significantly (Kratochvil et al. 2002).
Atomoxetine is of particular interest for the
treatment of PDD from the perspective of its
possible enhancing effect on social behavior in
depressed patients and normal subjects (Tse
and Bond 2002). To date, only one small study
retrospectively assessed the effect of atomoxe-
tine in 20 children and adolescents with PDD,
of whom 12 patients appeared to respond fa-
vorably (Jou et al. 2005). Therefore, the pri-
mary purpose of this study was to evaluate the
tolerability and effectiveness of atomoxetine in
the treatment of attention problems, hyperac-
tivity, and impulsivity in children with PDD,
whereas as a secondary purpose we sought to
evaluate the possible response to atomoxetine
on the core symptoms of PDD.
METHOD
Subjects
Study participants who were 6–17 years of
age were recruited from referred patients of
the Groningen University Child and Adoles-
cent Psychiatry Center and the Youth Depart-
ment of the Groningen Center for Mental
Health, both ambulatory centers. All children
had to meet Diagnostic and Statistical Manual
of Mental Disorders, 4th edition, text revision
(DSM-IV-TR) criteria (American Psychiatric
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Association 2000) for a PDD, that is, autistic
disorder, Asperger’s disorder, or a PDD not
otherwise specified (PDDNOS). These diag-
noses were established by clinical assessment,
corroborated by algorithm cutoff scores on the
Autism Diagnostic Interview (ADI)-Revised.
The ADI is a semistructured method of elicit-
ing information from a parent to confirm a
clinical impression of autism in children and
adults. The interview was developed by Lord
and colleagues (1994) and has demonstrated
excellent reliability and validity for the diag-
nosis of autistic disorder (Rutter et al. 2003).
Two interviewers were trained in administer-
ing and scoring the interview. All interviewers
had reached 80% reliability in scoring the ADI-
R, as required. 
Moreover, patients were required to meet
the DSM-IV-TR criteria for ADHD by clinical
assessment and also had to have a symptom
severity score at least 1.7 SD above age and
gender norms on the total, the inattentive, or
the hyperactivity/impulsive subscale scores
on the ADHD Rating Scale-IV-Parent Ver-
sion, Investigator Administered and Scored
(ADHDRS) (DuPaul et al. 1998). 
Children on effective psychotropic drug
treatment for ADHD symptoms were ex-
cluded. Other exclusion criteria included an
intelligence quotient lower than 70 as assessed
by the Wechsler Intelligence Scale for Chil-
dren, 3rd edition (Wechsler 1991), presence of a
serious medical illness, of co-morbid psy-
chosis or bipolar disorder, a history of seizure
disorder, or ongoing use of psychoactive med-
ications other than the study drug.
The aim and procedure of the study were
fully explained to the subjects and their par-
ents before the parents’ written consent was re-
quested. If the subject was 12 years or older, the
written assent of the subject was obtained along
with the consent of the parents. The study was
reviewed and approved by the Groningen Uni-
versity Hospital’s ethical review board and was
in accordance with the Helsinki Declaration of
1975, as revised in 2000. 
Measures
Weekly ratings included the Investigator
Administered and Scored ADHDRS, the Clini-
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cal Global Impression Scale of severity with re-
gard to ADHD symptoms (CGI-ADHD-S), and
the short form of the Conners’ Parent Rating
Scale—Revised (CPRS-R). The ADHDRS con-
tains 18 items that correspond with the DSM-
IV ADHD symptoms, whereby each item is
scored on a 3-point scale, thus assessing the
ADHD severity over the past week. The total
score is computed as the sum of the scores on
each of the 18 items (DuPaul et al. 1998). The
CPRS-R is a 28-item rating scale completed by
parents to assess problem behaviors related to
ADHD (Conners 1997). The Aberrant Behavior
Checklist (ABC) was rated every 2 weeks. The
ABC is a well-validated instrument in specifi-
cally assessing PDD-related problems (Aman
et al. 1985).
Safety and tolerability were assessed by
weekly open-ended questioning for adverse
events and monitoring of vital signs. Routine
laboratory tests, electrocardiography, and
physical evaluation were performed at pre-
treatment and at study end. All ECG’s were re-
viewed by a child cardiologist.
Design and procedures
After an initial 3- to 28-day evaluation and
medication wash-out period, patients were
treated for 10 weeks with atomoxetine in an
open-label fashion during the period from Jan-
uary through October, 2004. Atomoxetine was
started at 0.5 mg/kg/day for 4 days, 0.8 mg/
kg/day for 3 days, and furthermore titrated to
a target dose of 1.2 mg/kg/day with flexibility
of dose between 0.5 mg/kg/day and 1.8 mg/
kg/day, on the basis of efficacy and tolerabil-
ity. The total dose was administered as a single
daily dose in the morning or as a twice daily
divided dose, based on patient-preference or
side effects.
Data analysis
The primary efficacy measure was the base-
line to endpoint change in ADHDRS severity.
Secondary analyses included change in CPRS-
R and ABC subscores. Intent-to-treat analyses
were applied to outcome measures from all
patients enrolled for ongoing therapy. If a pa-
tient withdrew from the study prior to study
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completion, data were examined by using the
last observation carried forward model. De-
scriptive statistics were presented as mean ±
SD. Differences between baseline and end-of-
study were examined using Wilcoxon signed
rank tests (two-tailed). In all tests, p values of
less than 0.05 were used to indicate statistical
significance. Effect sizes were computed to
evaluate the magnitude of changes (Cohen
1988). As this was a pilot study, corrections for
multiple comparisons were not made.
RESULTS
Subjects
Of the 47 patients who initially showed in-
terest to participate, 20 did not meet inclusion
criteria (9 patients did not meet DSM-IV-TR
criteria for a PDD and/or ADHD, 7 patients
because of efficacy of current psychotropic
drug treatment for ADHD symptoms, 1 pa-
tient because of an intelligence quotient lower
than 70, 1 patient was not able to swallow cap-
sules, and 2 patients did not consent for a veni-
puncture) and 15 were unwilling to give final
consent, mostly for logistic reasons. The re-
maining 12 patients (10 males), with a mean
age of 10.2 ± 2.8 years (range 6–14 years) and a
mean body weight of 41.4 ± 11.8 kg were en-
rolled and started open label treatment with
atomoxetine. Six out of 12 children had a diag-
nosis of autistic disorder, 5 out of 12 a diagno-
sis of PDDNOS, and 1 child a diagnosis of
Asperger’s disorder. All patients had been
treated the previous year with psychoactive
medications, mostly psychostimulants (Table
1). Ten patients (83%) completed at least 6
weeks of the study, and 7 patients (58%) com-
pleted the whole study. Five patients (42%)
discontinued because of side effects.
Psychometric measurements
Table 2 summarizes baseline and end-of-
study ADHDRS, CPRS-R, and ABC scores of
the intent-to-treat population. Statistically sig-
nificant improvements were seen on the
AHDHRS-Total score (Fig. 1), on the CPRS-R
subscales “Hyperactivity,” “Cognitive Prob-
lems,” and “ADHD Index.” Changes on the
ABC only approached significance for im-
provement on the subscale “Hyperactivy” (p =
0.071); on the other scales no significant
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TABLE 1. CLINICAL CHARACTERISTICS OF 12 CHILDREN ENROLLED IN AN OPEN LABEL TREATMENT WITH ATOMOXETINE
Subject Age Gender DSM-IV-TR diagnosis of PDD Mental development Previous drugs
1 14.7 M Autistic disorder Average IQ Risperidone
Methylphenidate
2 12.8 M PDDNOS Borderline IQ Risperidone
Methylphenidate
Dextroamphetamine
3 7.2 M Autistic disorder Borderline IQ Risperidone
Methylphenidate
Pipamperone
4 14.8 M Autistic disorder Borderline IQ Methylphenidate
5 8.5 M Autistic disorder Borderline IQ Quetiapine
6 8.7 M Autistic disorder Borderline IQ Risperidone
Methylphenidate
7 6.0 F Autistic disorder Borderline IQ Risperidone
Methylphenidate
8 11.8 M PDDNOS Borderline IQ Pipamperone
9 9.3 M PDDNOS Borderline IQ Clonidine
Melatonin
10 8.6 M Asperger’s disorder Average IQ Dextroamphetamine
11 10.9 F PDDNOS Average IQ Dextroamphetamine
12 9.3 M PDDNOS Average IQ Methylphenidate
Melatonin
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changes were apparent. Except for the ABC
subscales “Inappropriate Speech” and “Irri-
tability”, all effect sizes were in the high range
(> 0.14). At end of the study, all 7 (58%) com-
pleters and 2 (17%) noncompleters were rated
as “much improved” or “very much im-
proved” on the CGI-ADHD-S scale. The re-
maining 3 noncompleters were rated as
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TABLE 2. EFFICACY OUTCOMES AT BASELINE AND END OF STUDY FOR 12 CHILDREN
WITH PERVASIVE DEVELOPMENTAL DISORDERS AND SYMPTOMS OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
TREATED FOR UP TO 10 WEEKS WITH ATOMOXETINEa
Measure Baseline End-of-Study pb z ESc
ADHD-Rating Scale-IV, Parent Version, 40.33 ± 5.61 22.42 ± 9.49 0.003 2.982 2.30
Investigator Scored-Total score
Conners’ Parent Rating Scale-R: S subscales
Oppositional subscale 9.17 ± 5.20 8.17 ± 5.59 0.609 0.512 0.19
Cognitive Problems subscale 12.42 ± 4.83 9.33 ± 4.48 0.028 2.197 0.66
Hyperactivity subscale 9.83 ± 3.93 6.67 ± 5.66 0.030 2.169 0.65
Attention Deficit Hyperactivity Disorder Index 4.25 ± 0.91 18.67 ± 9.83 0.023 2.273 0.63
Aberrant Behavior Checklist subscales
Irritability 15.83 ± 9.45 14.50 ± 12.82 0.610 0.511 0.12
Social Withdrawal 8.92 ± 5.85 7.17 ± 7.04 0.138 1.483 0.27
Stereotypy 3.42 ± 3.09 2.58 ± 3.31 0.140 1.476 0.26
Hyperactivity 23.58 ± 7.86 18.67 ± 13.78 0.071 1.806 0.44
Inappropiate Speech 3.33 ± 2.61 3.75 ± 3.67 0.478 0.710 0.13
aLast observation carried forward. Mean ± SD.
bComparison made with a two-tailed, Wilcoxon signed rank test.
cEffect sizes were calculated by dividing the difference in mean scores at baseline and end of study by the pooled
standard deviation.
FIG. 1. Mean attention-deficit/hyperactivity disorder (ADHD) ratings by week in children with ADHD and perva-
sive developmental disorders (PDDs) on atomoxetine (n = 12).
14346C09.pgs  10/18/06  1:49 PM  Page 615
“minimally improved” (8%), “no change”
(8%), and “minimally worse” (8%) respectively.
Medication dosing and tolerability
The mean maximum total daily dose (TDD)
of atomoxetine prescribed ranged from 0.49
mg/kg/day to 1.72 mg/kg/day, with an over-
all mean TDD of 1.19 ± 0.41 mg/kg/day. The
actual TDD ranged from 17.5 mg/day to 80
mg/day. A total of 5 patients (42%) did not
complete the study because of side effects: 
1 patient after receiving one dose of atomoxe-
tine because of nausea, 1 patient after 3 weeks
because of anxiety, 1 patient after 6 weeks
because of increased aggression/agitation, 
1 patient after 8 weeks because of nausea/
vomiting, and 1 patient after 9 weeks because
of loss of appetite and (for the parents) unac-
ceptable weight loss (3.3 kg). The most com-
mon side effects reported were anorexia (n =
10), irritability (n = 9), and sleeping problems
(n = 7) (Table 3). All side effects were in the
mild-to-moderate-range. Mean heart rate in-
creased (85 vs. 93 beats per minute, baseline
versus endpoint, respectively; p < 0.022), no
differences were observed in blood pressure.
Analysis of electrocardiograms (ECGs) re-
vealed no evidence of effects of atomoxetine
on mean conduction, repolarization, or
rhythm (PR, QRS, and QTc intervals all un-
changed). There were no clinically meaning-
ful changes in vital signs and individual or
mean laboratory test results, including liver
function tests.
DISCUSSION
To our knowledge, this is the first prospec-
tive study on the effectiveness of atomoxetine
in children with PDD. The data of this open
label pilot study suggest several preliminary
findings. First, these findings indicate that ato-
moxetine may well be effective in reducing hy-
peractivity, inattention, and impulsivity in
children with PDD. All 7 completers appeared
to have derived substantial clinical benefit,
and nearly all ADHD-related instruments
showed a statistical improvement from base-
line to end-of-study, with only improvement
on the ABC subscale “Hyperactivity” being
not significant (p = 0.071). This is in line with
the findings of a recently completed retrospec-
tive study in 20 children and adolescents with
PDD, in which almost two thirds of the sub-
jects showed a beneficial response in the con-
duct, hyperactivity, inattention, and learning
domains (Jou et al. 2005). We found no im-
provement, and no worsening either on any of
the other ABC subscales, including “Irritabil-
ity,” “Stereotypy,” and “Social Withdrawal.”
Also, there was no improvement on the “Op-
positional” subscale of the CPRS-R. This indi-
cates that atomoxetine may not be effective for
any of the behavior problems that are fre-
quently associated with PDD. There were no
clinically meaningful changes in individual or
mean laboratory tests, and in particular, given
the recent warning in the Physician Package
Insert (PI), there was no significant increase in
liver function tests.
Also of note is that 5 out of 12 children ter-
minated the study as a result of side effects: 3
children because of gastrointestinal com-
plaints and the other 2 children due to anxiety
and increased aggression. Although gastroin-
testinal symptoms such as loss of appetite,
stomach ache, and vomiting are known side
effects of atomoxetine, these have only infre-
quently led to discontinuation in nonautistic
children (Gillberg et al. 2003). Apparently, chil-
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TABLE 3. SIDE EFFECTS REPORTED IN 12 CHILDREN
WITH PERVASIVE DEVELOPMENTAL DISORDERS AND SYMPTOMS
OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER TREATED












aIncidence of Adverse Events Reported in at least 10%
of atomoxetine-treated subjects.
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dren with PDDs may be more vulnerable to
experience atomoxetine-associated side effects
than nonautistic children. This surely should
be studied more extensively in future con-
trolled studies involving a larger number of
patients. Other reported side effects included
sleeping problems, drowsiness, constipation,
and increased heart rate, all in the mild-to-
moderate-range. A relatively high proportion
of children had symptoms of irritability, ag-
gression, and tearfulness, which might be re-
lated to the symptom cluster of irritability,
hostility, and suicidality, which has recently
been listed in the PI of atomoxetine-specific
comments. Whether these symptoms, or any
of the other psychiatric side effects, were a true
drug effect remains uncertain, given the non-
placebo-controlled nature of the study. More-
over, PDDs in itself are well known to be
associated with a wide range of often fluctuat-
ing behavior problems such as aggression,
sleep problems, anxiety, and extreme sensitiv-
ity to changes.
This study had some clear limitations that
should be addressed in future studies. The
number of patients was small and it was not
blinded nor placebo controlled. The mean age
was 10.2 years, and more than 80% were
male, making the findings possibly less ac-
countable for adolescents and females. The
population being studied included only rela-
tively high-functioning subjects, indicating
the need for some cautiousness in generaliz-
ing the findings to the more impaired autism
population. 
In conclusion, these preliminary findings in-
dicate that atomoxetine may be a promising
new agent in the treatment of ADHD symp-
toms not only in typically developing children
but also in children with PDD. The possibly
higher vulnerability of children with PDD for
atomoxetine–associated side effects makes a
slower dose titration advisable. However,
these side effects should be viewed against the
known problems associated with alternative
medications (stimulants and antipsychotics) in
patients with PDD. Clearly, the improvements
observed in this trial call for future prospective
double-blind studies involving larger num-
bers of participants.  
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